DCTHNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
DELCATH SYSTEMS, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$14.37+0.29 (+2.06%)
Close on Oct 19, 2026
- Market cap
- $571.37M
- P/E (TTM)
- 1437.0
- Dividend yield
- –
DELCATH SYSTEMS, INC. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HEPZATO KIT | $27.16M | $23.25M | $19.06M | $19.25M | $22.50M | $18.02M | $13.69M | $10.04M | $6.57M | $2.01M | $0 | $0 | 93.2% | +20.7% |
| CHEMOSAT | $1.97M | $1.75M | $1.67M | $1.31M | $1.66M | $1.76M | $1.41M | $1.16M | $1.20M | $1.13M | $539.00K | $434.00K | 6.8% | +19.1% |
| Product revenue | – | – | – | – | – | – | – | – | – | – | $539.00K | $434.00K | – | – |
| Other revenue | – | – | – | – | – | – | – | – | – | – | $0 | $0 | – | – |
By region
| Revenue | Q2 26 | Q1 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | Q4 23 | Q3 23 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $27.16M | $23.25M | – | – | $22.50M | $18.02M | – | – | – | – | – | – | 93.2% | +20.7% |
| Foreign | $1.97M | $1.75M | – | – | $1.66M | $1.76M | – | – | – | – | – | – | 6.8% | +19.1% |
From the segment and revenue-disaggregation notes of Delcath Systems's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.